The relationship of serum lipoprotein lipase mass with fasting serum apolipoprotein B-48 and remnant-like particle triglycerides in type 2 diabetic patients

Hormone and Metabolic Research

Volumn 39, Issue 8, 2007, Pages 612-616

  Kobayashi, J ^a   Nakajima, K ^b   Nohara, A ^a   Kawashiri, M ^a   Yagi, K ^a   Inazu, A ^a   Koizumi, J ^c   Yamagishi, M ^a   Mabuchi, H ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Nakajima Associate   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Body mass index; Chylomicrons; ELISA; HDL cholesterol; Plasma glucose

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B48; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; AGED; APOLIPOPROTEIN B-48; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; REGRESSION ANALYSIS; SEX CHARACTERISTICS; TRIGLYCERIDES;

BOVINAE;

EID: 34548328276     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984473     Document Type: Article

References (40)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219
2. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JD, Gotto Jr AM, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Arterioscler Thromb 1992; 12: 1336-1345
3. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995; 41: 153-158
4. Miensenbock G, Patsch JR. Postprandial hyperlipidemia: the search for the atherogenic lipoprotein. Curr Opin Lipidol 1992; 3: 196-201
5. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5: 102-119
6. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1995; 6: 123-129
7. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-485
8. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high-density lipoproteins during alimentary lipemia in man. J Clin Invest 1973; 52: 32-38
9. Nilsson-Ehle P, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Ann Rev Biochem 1980; 49: 667-693
10. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo C-II deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds). The metabolic and molecular basis of inherited disease. New York: Mc Graw-Hill Inc., 2001; 2789-2816
11. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, Saito Y. Pre-heparin plasma lipoprotein lipase mass: Its correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 2001; 33: 412-416
12. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 2002; 56: 181-187
13. Kobayashi J, Maruyama T, Watanabe H, Kudoh A, Tateishi S, Sasaki T, Murano S, Watanabe M. Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population. Diabetes Res Clin Pract 2003; 62: 39-45
14. Kobayashi J. Pre-heparin lipoprotein lipase mass. J Atheroscler Thromb 2004; 11: 1-5
15. Kobayashi J, Tateishi S, Maruyama T, Kudoh A, Murano S. Marked reduction in serum high-density lipoprotein cholesterol levels in a woman with acute inflammation due to diabetic gangrene. Clin Chim Acta 2003; 335: 33-38
16. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama S, Suzuki K, Nakamura Y, Yamatani K, Aizawa Y. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 2004; 174: 385-390
17. Rip J, Nierman MC, Wareham NJ, Luben R, Bingham SA, Day NE, Miert JN van, Hutten BA, Kastelein JJ, Kuivenhoven JA, Khaw KT, Boekholdt SM. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2006; 26: 637-642
18. Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S, Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 2001; 357: 657-663
19. ChanL, Chang BH, Nakamuta M, Li WH, Smith LC. Apobec-1 and apolipoprotein B mRNA editing. Biochim Biophys Acta 1997; 1345: 11-26
20. Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-193
21. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tamari Y, Kihara S, Hiraoka H, Nakamura T, Ito S, Yamashita S, Matsuzawa Y. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003; 44: 1256-1262
22. Nakajima K, Okazaki M, Tanaka A et al. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apo B-100 and apo A-1. J Clin Ligand Assay 1996; 19: 177-183
23. Cohn JS, Marcoux C, Davignon J. Detection, quantification and characterization of potential atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19: 2474-2486
24. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 1992; 33: 369-380
25. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987; 79: 1110-1119
26. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150: 167-177
27. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000; 148: 283-291
28. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism 2005; 54: 689-697
29. Kobayashi J, Nohara A, Kawashiri MA, Inazu A, Koizumi J, Nakajima K, Mabuchi H. Serum lipoprotein lipase mass: Clinical significance of its measurement. Clin Chim Acta 2007; 378: 7-12
30. Auwerx JH, Babirak SP, Fujimoto WY, Iverius PH, Brunzell JD. Defective enzyme protein in lipoprotein lipase deficiency. Eur J Clin Invest 1989; 19: 433-437
31. Kern PA, Martin RA, Carty J, Goldberg IJ, Ong JM. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type I hyperlipoproteinemia. J Lipid Res 1990; 31: 17-26
32. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin injection. Arterioscler Thromb Vasc Biol 1995; 15: 1086-1093
33. Tornvall P, Karpe F, Proudler A, Bavenholm P, Landou C, Olivecrona T, Hamsten A. High-density lipoprotein: Relations to metabolic parameters and severity of coronary artery disease. Metabolism 1996; 45: 1375-1382
34. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, Shirai K. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 2000; 153: 391-396
35. Hitsumoto T, Yoshinaga K, Aoyagi K, Sakurai T, Kanai M, Uchi T, Noike H, Ohsawa H, Watanabe H, Shirai K. Association between preheparin serim lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb 2002; 9: 163-169
36. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K. Preheparin serum lipoprotein lipase mass level: The effects of age, gender and type of hyperlipidemia. Atherosclerosis 1999; 145: 45-50
37. Hirano T, Nishioka F, Murakami T. Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: Comparison with postheparin plasma. Metabolism 2004; 53: 526-531
38. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita , Shirai K. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2006, Sep 4; [Epub ahead of print]
39. Kobayashi J, Kusunoki M, Murase Y, Kawashiri M, Higashikata T, Miwa K, Katsuda S, Takata M, Asano A, Nohara A, Inazu A, Mabuchi H. Relationship of lipoprotein lipase and hepatic triacylglycerol lipase activity to serum adiponectin levels in Japanese hyperlipidemic men. Horm Metab Res 2005; 37: 505-509
40. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanism by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins: Roles for low density lipoprotein receptors and heparan sulphate proteoglycans. J Biol Chem 1992; 267: 13284-13292